scholarly journals LONG-TERM FOLLOW-UP OF THE COMPARE-AMI TRIAL: COMPARISON OF INTRACORONARY INJECTION OF CD133+ BONE MARROW STEM CELLS TO PLACEBO IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION WITH LEFT VENTRICULAR DYSFUNCTION

2018 ◽  
Vol 34 (10) ◽  
pp. S141
Author(s):  
K. Haddad ◽  
B. Potter ◽  
A. Matteau ◽  
F. Gobeil ◽  
L. Stevens ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Stem Cells ◽  
Bone Marrow ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Left Ventricular ◽  
Long Term Follow Up

scholarly journals One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133+ Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Samer Mansour ◽  
Denis-Claude Roy ◽  
Vincent Bouchard ◽  
Louis Mathieu Stevens ◽  
Francois Gobeil ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Stem Cells ◽  
Bone Marrow ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Safety Analysis ◽  
Left Ventricular ◽  
Intracoronary Injection ◽  
One Year

Bone marrow stem cell therapy has emerged as a promising approach to improve healing of the infarcted myocardium. Despite initial excitement, recent clinical trials using non-homogenous stem cells preparations showed variable and mixed results. Selected CD133+ hematopoietic stem cells are candidate cells with high potential. Herein, we report the one-year safety analysis on the initial 20 patients enrolled in the COMPARE-AMI trial, the first double-blind randomized controlled trial comparing the safety, efficacy, and functional effect of intracoronary injection of selected CD133+ cells to placebo following acute myocardial infarction with persistent left ventricular dysfunction. At one year, there is no protocol-related complication to report such as death, myocardial infarction, stroke, or sustained ventricular arrhythmia. In addition, the left ventricular ejection fraction significantly improved at four months as compared to baseline and remained significantly higher at one year. These data indicate that in the setting of the COMPARE-AMI trial, the intracoronary injection of selected CD133+ stem cells is secure and feasible in patients with left ventricle dysfunction following acute myocardial infarction.

scholarly journals Transplantation of Bone Marrow-Derived Very Small Embryonic-Like Stem Cells Attenuates Left Ventricular Dysfunction and Remodeling After Myocardial Infarction

Stem Cells ◽  
2008 ◽  
Vol 26 (6) ◽  
pp. 1646-1655 ◽  
Author(s):  
Buddhadeb Dawn ◽  
Sumit Tiwari ◽  
Magdalena J. Kucia ◽  
Ewa K. Zuba-Surma ◽  
Yiru Guo ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Stem Cells ◽  
Bone Marrow ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Left Ventricular

Abstract 4305: Long-term Follow-up Of Left Ventricular Function After Acute Myocardial Infarction Treated With Intracoronary Injection Of Autologous Bone Marrow Cells. The ASTAMI Study

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Jan Otto Beitnes ◽  
Einar Hopp ◽  
Ketil Lunde ◽  
Hans-Jørgen Smith ◽  
Svein Solheim ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Bone Marrow ◽  
Left Ventricular Function ◽  
Bone Marrow Cells ◽  
Left Ventricular ◽  
Intracoronary Injection ◽  
Significant Difference

Background: Long-term effects of cardiac autologous cell therapy are not well known. We performed a 3 year follow-up of the ASTAMI study. Patients with acute ST-elevation anterior wall myocardial infarctions were initially randomized to either intracoronary injection of autologous mononuclear bone marrow cells (mBMCs) (n=50) or control (n=50). At 6 months, LV ejection fraction improved in both groups, with no significant difference between groups. Methods: All eligible patients underwent MRI with a 1,5 T scanner (Siemens) 2–3 weeks, 6 months and mean(SD) 3,2 (0,2) years after myocardial infarction and stem cell injection. Infarct size was determined from gadolinium late-enhancement MR images. All images were analyzed by experienced observers blinded for treatment assignment. Left ventricular volumes were calculated by the area-length method. Results: There was no significant difference in EDV, ESV or LVEF between baseline and 3 years in neither group. Infarction volume was reduced at 3 years in both groups (p<0,001). No significant effects of mBMC treatment could be identified on LV volumes, LVEF or infarct size. Thus intracoronary injection of mBMCs in acute myocardial infarction does not improve global LV function over a 3 year follow-up. Left ventricular function after mBMC-treatment

Sign in / Sign up

Export Citation Format

Share Document